The FDA approved cefepime/enmetazobactam (Exblifep) in February 2024 for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms in patients...
The study, co-authored by cranberry expert Dr. Amy Howell, used a combination of in vitro bioassays and ex vivo urine analyses to compare the anti-adhesion activity of the two...